Format

Send to

Choose Destination
Oncotarget. 2016 Mar 15;7(11):12904-16. doi: 10.18632/oncotarget.7354.

Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer.

Author information

1
Structural Biochemistry Laboratory, Centro de Investigación Príncipe Felipe, Valencia, Spain.
2
Molecular Oncology Laboratory, Fundación para la Investigación del Hospital General Universitario, Valencia, Spain.
3
Instituto de Investigación Sanitaria La Fe, Hospital Universitario i Politécnico La Fe, Valencia, Spain.
4
Computational Genomics Department, Centro de Investigación Príncipe Felipe, Valencia, Spain.
5
Department of Medical Oncology, Consorcio Hospital General Universitario, Valencia, Spain.
6
Bioinformatics of Rare Diseases (BIER), CIBER de Enfermedades Raras (CIBERER), Valencia, Spain.
7
Functional Genomics Node, Instituto Nacional de Bioinformática / Centro de Investigación Príncipe Felipe, Valencia, Spain.
8
Department of Medicine, Universitat de València, Valencia, Spain.

Abstract

Lung cancer (LC) is responsible for most cancer deaths. One of the main factors contributing to the lethality of this disease is the fact that a large proportion of patients are diagnosed at advanced stages when a clinical intervention is unlikely to succeed. In this study, we evaluated the potential of metabolomics by 1H-NMR to facilitate the identification of accurate and reliable biomarkers to support the early diagnosis and prognosis of non-small cell lung cancer (NSCLC).We found that the metabolic profile of NSCLC patients, compared with healthy individuals, is characterized by statistically significant changes in the concentration of 18 metabolites representing different amino acids, organic acids and alcohols, as well as different lipids and molecules involved in lipid metabolism. Furthermore, the analysis of the differences between the metabolic profiles of NSCLC patients at different stages of the disease revealed the existence of 17 metabolites involved in metabolic changes associated with disease progression.Our results underscore the potential of metabolomics profiling to uncover pathophysiological mechanisms that could be useful to objectively discriminate NSCLC patients from healthy individuals, as well as between different stages of the disease.

KEYWORDS:

NSCLC; biomarkers; early diagnosis; metabolomics; prognosis

PMID:
26883203
PMCID:
PMC4914330
DOI:
10.18632/oncotarget.7354
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center